[18F]FLT and [18F]FDG PET for Non-invasive Treatment Monitoring of the Nicotinamide Phosphoribosyltransferase Inhibitor APO866 in Human Xenografts |
| |
| Authors: | Mette Munk Jensen Kamille Dumong Erichsen Camilla Bardram Johnbeck Fredrik Bj?rkling Jacob Madsen Michael Bzorek Peter Buhl Jensen Liselotte H?jgaard Maxwell Sehested Andreas Kj?r |
| |
| Institution: | 1. Cluster for Molecular Imaging, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.; 2. Department of Clinical Physiology, Nuclear Medicine and PET, Rigshospitalet, Copenhagen, Denmark.; 3. TopoTarget A/S, Symbion Science Park, Copenhagen, Denmark.; 4. Department of Pathology, Næstved Hospital, Næstved, Denmark.; The University of Chicago, United States of America, |
| |
| Abstract: | IntroductionAPO866 is a new anti-tumor compound inhibiting nicotinamide phosphoribosyltransferase (NAMPT). APO866 has an anti-tumor effect in several pre-clinical tumor models and is currently in several clinical phase II studies. 3′-deoxy-3′-18F]fluorothymidine (18F]FLT) is a tracer used to assess cell proliferation in vivo. The aim of this study was non-invasively to study effect of APO866 treatment on 18F]FLT and 2-deoxy-2-18F]fluoro-D-glucose (18F]FDG) uptake.Methods
In vivo uptake of 18F]FLT and 18F]FDG in human ovary cancer xenografts in mice (A2780) was studied at various time points after APO866 treatment. Baseline 18F]FLT or 18F]FDG scans were made before treatment and repeated after 24 hours, 48 hours and 7 days. Tumor volume was followed with computed tomography (CT). Tracer uptake was quantified using small animal PET/CT. One hour after iv injection of tracer, static PET scans were performed. Imaging results were compared with Ki67 immunohistochemistry.ResultsTumors treated with APO866 had volumes that were 114% (24 h), 128% (48 h) and 130% (Day 7) relative to baseline volumes at Day 0. In the control group tumor volumes were 118% (24 h), 145% (48 h) and 339% (Day 7) relative to baseline volumes Day 0. Tumor volume between the treatment and control group was significantly different at Day 7 (P = 0.001). Compared to baseline, 18F]FLT SUVmax was significantly different at 24 h (P<0.001), 48 h (P<0.001) and Day 7 (P<0.001) in the APO866 group. Compared to baseline, 18F]FDG SUVmax was significantly different at Day 7 (P = 0.005) in the APO866 group.ConclusionsAPO866 treatment caused a significant decrease in 18F]FLT uptake 24 and 48 hours after treatment initiation. The early reductions in tumor cell proliferation preceded decrease in tumor volume. The results show the possibility to use 18F]FLT and 18F]FDG to image treatment effect early following treatment with APO866 in future clinical studies. |
| |
| Keywords: | |
|
|
